Medicine-induced Cardiac Hemodialysis on COVID-19

• Status: Completed
• Trial end date: 2023-01-12
• Target enrollment: 0
• Participant gender: All

Summary

The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system. The clinical trial hypothesizes that SARS-CoV-2 human pathogen arises from immune attacks, underlying the severe physiological symptoms that can be lethal. It further hypothesizes that the vaccines do not deal with the Spike 2 protein that causes the immune attacks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yang I. Pachankis
• Treatments: alpha-Tocopherol; Coenzyme Q10; Duloxetine Hydrochloride; Enalapril; Enalaprilat; Lansoprazole; Metoprolol; Nifedipine; Superoxide Dismutase; Tocopherols; Ubiquinone; Vitamin E

Criteria

Inclusion Criteria:

• No mRNA vaccinated poisoning have been included currently, but scientific evidence suggest the methods of vaccination are irrelevant to the conditions. It is theorized that the more advanced the vaccine production technology, the deeper the poisoning.

Exclusion Criteria:

• healthy individuals with no myocarditis or unvaccinated without infection by SARS-CoV series

• persons with diabetes (Paxlovid and PrEP treatments can be applied according to availability)